SYLMAR, Calif.--(BUSINESS WIRE)--A new implantable technology has the potential to bring light back to blind individuals with Retinitis Pigmentosa (RP). Second Sight® Medical Products, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) to conduct a clinical study of the ArgusTM II Retinal Prosthesis System at centers of excellence across the United States.
